Literature DB >> 29528247

Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients.

Paulus S Rommer1, Uwe K Zettl2.   

Abstract

INTRODUCTION: Multiple sclerosis (MS) is an immune-mediated and neurodegenerative disease with an unpredictable outcome. Immune-modulatory treatment aims at decreasing long-term disability. With the increasing number of treatment options, it is essential to fully digest the possible side effects of the available therapeutics and to monitor patients is essential. AREAS COVERED: All approved disease-modifying drugs (DMD) for MS are discussed in this review. Mode of action, adverse effects, reported risks for infections and malignancies, and pregnancy related issues are discussed in the review. The authors also provide suggestions for monitoring therapy. For all approved DMDs the pivotal studies have been included for possible side effects, as well as reports by health authorities. For this manuscript, PubMed was checked for reports on side effects for various drugs. EXPERT OPINION: Treatment options in MS are manifold, each carrying different risks. The safety-risk profile for approved agents is favorable. Knowing and monitoring these possible side effects is essential to minimize risks associated with treatment. Presently, the long-term experience for some of these therapies is missing and this must be addressed.

Entities:  

Keywords:  Multiple sclerosis; alemtuzumab; cladribine; daclizumab; dimethylfumarate; fingolimod; glatiramer acetate; interferon beta; natalizumab; ocrelizumab; teriflunomide

Mesh:

Substances:

Year:  2018        PMID: 29528247     DOI: 10.1080/14656566.2018.1446944

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  24 in total

Review 1.  [Indications for varicella zoster and herpes zoster vaccination in multiple sclerosis: current situation].

Authors:  Alexander Winkelmann; Micha Löbermann; Uwe K Zettl
Journal:  Nervenarzt       Date:  2019-12       Impact factor: 1.214

2.  Leukocyte Telomere Length in Patients with Multiple Sclerosis and Its Association with Clinical Phenotypes.

Authors:  Michael Hecker; Brit Fitzner; Kathrin Jäger; Jan Bühring; Margit Schwartz; Alexander Hartmann; Michael Walter; Uwe Klaus Zettl
Journal:  Mol Neurobiol       Date:  2021-02-05       Impact factor: 5.590

3.  Ocrelizumab-induced alopecia areata-A series of five patients from Ontario, Canada: A case report.

Authors:  Laura D Chin; Mohn'd AbuHilal
Journal:  SAGE Open Med Case Rep       Date:  2020-05-06

4.  Multi-drug use among patients with multiple sclerosis: A cross-sectional study of associations to clinicodemographic factors.

Authors:  Niklas Frahm; Michael Hecker; Uwe Klaus Zettl
Journal:  Sci Rep       Date:  2019-03-06       Impact factor: 4.379

Review 5.  Immunological Aspects of Approved MS Therapeutics.

Authors:  Paulus S Rommer; Ron Milo; May H Han; Sammita Satyanarayan; Johann Sellner; Larissa Hauer; Zsolt Illes; Clemens Warnke; Sarah Laurent; Martin S Weber; Yinan Zhang; Olaf Stuve
Journal:  Front Immunol       Date:  2019-07-11       Impact factor: 7.561

6.  Clinical and immunological control of experimental autoimmune encephalomyelitis by tolerogenic dendritic cells loaded with MOG-encoding mRNA.

Authors:  Judith Derdelinckx; María José Mansilla; Maxime De Laere; Wai-Ping Lee; Juan Navarro-Barriuso; Inez Wens; Irene Nkansah; Jasmijn Daans; Hans De Reu; Aneta Jolanta Keliris; Johan Van Audekerke; Verdi Vanreusel; Zoë Pieters; Annemie Van der Linden; Marleen Verhoye; Geert Molenberghs; Niel Hens; Herman Goossens; Barbara Willekens; Patrick Cras; Peter Ponsaerts; Zwi N Berneman; Eva María Martínez-Cáceres; Nathalie Cools
Journal:  J Neuroinflammation       Date:  2019-08-15       Impact factor: 8.322

7.  Cognitive function in multiple sclerosis: A long-term look on the bright side.

Authors:  Yermi Harel; Alon Kalron; Shay Menascu; David Magalashvili; Mark Dolev; Glen Doniger; Ely Simon; Anat Achiron
Journal:  PLoS One       Date:  2019-08-29       Impact factor: 3.240

8.  Selenization of S. cerevisiae increases its protective potential in experimental autoimmune encephalomyelitis by triggering an intestinal immunomodulatory loop.

Authors:  Thais Fernanda de Campos Fraga-Silva; Luiza Ayumi Nishiyama Mimura; Larissa Ragozo Cardoso de Oliveira; Juliana Helena Dos Santos Toledo; Patrícia Aparecida Borim; Sofia Fernanda Gonçalvez Zorzella-Pezavento; Diego Peres Alonso; Paulo Eduardo Martins Ribolla; Carlos Alberto Ferreira de Oliveira; Denise Morais da Fonseca; Eduardo J Villablanca; Alexandrina Sartori
Journal:  Sci Rep       Date:  2020-12-17       Impact factor: 4.379

9.  Teriflunomide-exposed pregnancies in a French cohort of patients with multiple sclerosis.

Authors:  Astrid Barataud-Reilhac; Sandrine Kerbrat; Jonathan Roux; Alice Guilleux; Elisabeth Polard; Emmanuelle Leray
Journal:  Neurol Clin Pract       Date:  2020-08

10.  Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe.

Authors:  Carmen Alcalá; F Gascón; Francisco Pérez-Miralles; J A Domínguez; S Gil-Perotín; B Casanova
Journal:  J Neurol       Date:  2019-01-19       Impact factor: 6.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.